The overall goal of the proposed research is to evaluate the use of [11C]SY08 as a PET
radiotracer for aggregated alpha synuclein (αS) in individuals with Parkinson's disease (PD),
Multiple system atrophy (MSA), Dementia with Lewy Bodies (DLB) and healthy controls.
The purpose of this study is to evaluate the use of [11C]SY08 as a PET radiotracer for αS
fibrils in individuals with PD, MSA, DLB and healthy controls. The specific aims of the
current study are:
1. To determine brain uptake, distribution, and kinetics of [11C]SY08 in healthy
individuals.
2. To determine brain uptake, distribution, and kinetics of [11C]SY08 in patients with
alpha synuclein aggregates in the brain, including PD, DLB and MSA.
3. To determine human dosimetry of [11C]SY08 in healthy individuals
An intravenous bolus injection of [11C]SY08 will be administered per subject for brain PET
imaging.